GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
R

Roivant Sciences ROIV · USD

Health Care · US listing · 🇺🇸 United States

Compare

38.96

+0.59%

Close of 19 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

Price performance

Chart by TradingView, with its own licensed prices

Roivant Sciences — daily ROIV Delayed
Market value
$28.26bn
Last close × shares
Volume
4.9m
Shares, 19 Nov 2026

About Roivant Sciences

From its filings with the US Securities and Exchange Commission

SEC filings

Roivant Sciences is based in London and is incorporated in Bermuda. Its shares trade on Nasdaq under the ticker ROIV. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 March 2026, it reported revenue of $8.3m and a net loss of $299.8m. At that date it held total assets of $5.71bn and shareholders' equity of $4.53bn.

In its own words

Roivant is a biopharmaceutical company that aims to improve the lives of patients by accelerating the development and commercialization of medicines that matter. Roivant’s pipeline includes brepocitinib, a potent small molecule inhibitor of JAK1 and TYK2 currently under review at the FDA for the treatment of dermatomyositis and also in late stage development for the treatment of non-infectious uveitis, cutaneous sarcoidosis and lichen planopilaris; IMVT-1402, a fully human monoclonal antibody targeting FcRn in development across several IgG-mediated autoimmune indications; and mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease. We advance our pipeline by creating nimble subsidiaries or “Vants” to develop and commercialize our medicines and technologies. Beyond therapeutics, Roivant also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business.

Note: All product candidates in our current pipeline are investigational and subject to health authority approval. The “Phase” for a specific product candidate referenced above reflects both ongoing clinical trials and expected upcoming trials.

Quoted from its 10-K, filed 20 May 2026. Read the filing on SEC.gov ↗

More about Roivant Sciences →

How it makes its money

Revenue, year to 31 Mar 2024

  • Product revenue, net [Member] $75.1m · 60.1%
  • Represents the license, milestone, and other revenue. $24.9m · 20.0%

Latest on Roivant Sciences

Our reporting

Next results

5 Feb 2027

Due on 5 Feb 2027. Analysts expect earnings of -0.36 a share.

Other Health Care listings

Scenario calculator

Try your own numbers. This is arithmetic, not a forecast.

Interactive

Gain or loss

—

Return

—

Leaves out fees, taxes and financing.

Frequently asked questions

What is Roivant Sciences's ticker?

Roivant Sciences trades as ROIV on its US listing, under ISIN BMG762791017.

What was Roivant Sciences's last closing price?

38.96 on 19 Nov 2026. The figure is in USD and is never converted.

When does Roivant Sciences next report results?

Results are expected on 9 Nov 2026, according to our data supplier.

Sources and methodology

Chart
TradingView
Close and company data
SEC filings and our data supplier
News
Our reporting

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.